Guideline‐compliant prescription of biologicals and possible barriers in dermatological practices in Bavaria

Schielein, Maximilian; Tizek, Linda; Rotter, Markus; Konstantinow, Alexander; Biedermann, Tilo; Zink, Alexander

doi:10.1111/jdv.14811

Cited by 29 publications

(25 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[51][52][53][54][55][56][57][58][59] Finally, there is hope for new effective treatments for the severely affected patients with atopic eczema in the future. [51][52][53][54][55][56][57][58][59] Finally, there is hope for new effective treatments for the severely affected patients with atopic eczema in the future.…”

Section: Discussionmentioning

confidence: 99%

“…There is a silver streak of hope on the horizon with the appearance of new targeted therapies with biologics such as monoclonal antibodies against relevant cytokines or receptors, for example the interleukin 4 receptor (dupilumab), interleukin 5 (mepolizumab), interleukin 13 (tralokinumab), interleukin 31 (nemolizumab) as well as new kinase inhibitors and others. [51][52][53][54][55][56][57][58][59] Finally, there is hope for new effective treatments for the severely affected patients with atopic eczema in the future.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Atopic eczema: burden of disease and individual suffering – results from a large EU study in adults

Ring

Zink

Arents

et al. 2019

Acad Dermatol Venereol

Self Cite

128

112

View full text Add to dashboard Cite

Background Atopic eczema (AE, atopic dermatitis) is one of the most common non‐communicable inflammatory skin diseases affecting 1–5% of the adult population in Europe with marked impairment in quality of life. In spite of great progress in understanding the pathophysiology of disturbed skin barrier and immune deviation, AE still represents a problem in daily clinical practice. Furthermore, the true impact of AE on individual suffering is often not recognized. Objectives With a large European study, we wanted to provide insights into the actual suffering and individual burden of disease in adult patients with AE. Methods A total of 1189 adult patients (18–87 years, 56% female) with moderate to severe AE were recruited in nine European countries by dermatologists or allergists together with the help of patient organizations. A computer‐assisted telephone interview was performed by experienced interviewers between October 2017 and March 2018. The following instruments were used to assess severity or measure quality of life: Patient‐Oriented Eczema Measure (POEM), Dermatology Life Quality Index (DLQI), Hospital Anxiety and Depression Scale (HADS‐D) and a newly developed Atopic Eczema Score of Emotional Consequences (AESEC). Patients were also asked to self‐assess the severity of their disease. Results Despite current treatment, 45% of participants still had actual moderate to very severe AE in POEM. Due to their skin disease, 57% missed at least 1 day of work in the preceding year. DLQI showed moderate to extremely large impairment in 55%. According to HADS‐D, 10% scored on or above the threshold of eight points with signs of depressive symptoms. Assessed with AESEC, 57% were emotionally burdened with feelings such as ‘trying to hide the eczema’, ‘feeling guilty about eczema’, having ‘problems with intimacy’ and more. Of persons actually suffering from severe AE, 88% stated that their AE at least partly compromised their ability to face life. Conclusions This real‐life study shows that adults with a moderate to severe form of AE are suffering more than what would be deemed acceptable. There is a need for increased awareness of this problem among healthcare professionals, policymakers and the general public to support research in the development of new and more effective treatments and provide access to better and affordable health care for affected patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Atopic eczema: burden of disease and individual suffering – results from a large EU study in adults

Ring

Zink

Arents

et al. 2019

Acad Dermatol Venereol

Self Cite

128

112

View full text Add to dashboard Cite

show abstract

“…Within the last few years there have been substantial new discoveries in AE research which have made the development of new treatment strategies possible [19,20,[28][29][30][31][32][33]. With the introduction of new treatment options and especially the approval of the first biologic for AE in the USA and EU, financial discussions have emerged [34,35]. All the more important are full evaluations and characterizations of AE beyond the skin symptoms.…”

Section: Discussionmentioning

confidence: 99%

Atopic eczema score of emotional consequences—a questionnaire to assess emotional consequences of atopic eczema

Arents

Mensing²,

Seitz³

et al. 2019

Allergo J Int

Self Cite

View full text Add to dashboard Cite

Purpose Atopic eczema (AE, atopic dermatitis), one of the most common chronic skin diseases worldwide, can dramatically influence the lives of affected patients as well as the lives of their families. Despite the availability of several questionnaires for assessing the impairment of quality of life, so far the emotional consequences of AE have received limited attention. The purpose therefore was to develop an instrument to assess the emotional consequences of AE in affected adults. Methods The Atopic Eczema Score of Emotional Consequences (AESEC) was developed based on a review of available instruments and by consulting individuals with AE about the emotional consequences of AE through social media. Validation was performed in a test-sample, followed by a large cross-sectional study in patients with AE across nine European countries. AESEC results were compared with the Patient Oriented Eczema Measure (POEM), the Dermatology Life Quality Index (DLQI) and the Hospital Anxiety and Depression Scale (HADS). Results A 28-item questionnaire on emotional consequences of having AE was developed. Applied to 1189 participants, AESEC showed high reliability and correlated well with DLQI, HADS and POEM. More than

show abstract

“…The most frequently consulted therapist was a GP (39.3%), which could be explained by the fact that there are more GPs than other specialists across the lower region of Bavaria. GPs are often the only available doctors for patients, especially in rural areas [ 26 , 27 ].…”

Section: Discussionmentioning

confidence: 99%

Prevalence and treatment of allergies in rural areas of Bavaria, Germany: a cross-sectional study

Boehmer

Schuster

Krause

et al. 2018

World Allergy Organization Journal

View full text Add to dashboard Cite

BackgroundThere is a high prevalence of allergies in Germany, with approximately 20% of the population having at least one allergy and only about 10% of these being treated adequately. We conducted a cross-sectional study in a rural area of Bavaria (Southern Germany) to evaluate the prevalence of allergies and their treatment, because research regarding this topic is currently limited.MethodsData were collected in 10 offices of non-dermatological doctors using a self-filled questionnaire to ask participants about allergies and treatment.ResultsA total of 641 questionnaires were appropriate for analysis. The prevalence of allergies in the Bavarian countryside was higher than that reported for Germany (37.3% vs. 20.0%). Furthermore, almost a third (30.4%) of allergies were not treated at all. The most frequently consulted therapist was found to be a general practitioner.ConclusionsBased on the study results, there is a need for prevention programs and establishment of treatments for certain allergies to minimize long-term health effects. Moreover, more studies are needed to analyze the prevalence of allergies in farmers who had a higher prevalence of allergies compared to previously reported prevalence in literature reviews.Trial registrationsThe study was approved by the ethical review committee of the Technical University Munich (EC number 548/16S).

show abstract

Guideline‐compliant prescription of biologicals and possible barriers in dermatological practices in Bavaria

Cited by 29 publications

References 26 publications

Atopic eczema: burden of disease and individual suffering – results from a large EU study in adults

Atopic eczema: burden of disease and individual suffering – results from a large EU study in adults

Atopic eczema score of emotional consequences—a questionnaire to assess emotional consequences of atopic eczema

Prevalence and treatment of allergies in rural areas of Bavaria, Germany: a cross-sectional study

Contact Info

Product

Resources

About